Disruptive mood dysregulation disorder at the age of 6 years and clinical and functional outcomes 3 years later
- PMID: 26786551
- PMCID: PMC5278560
- DOI: 10.1017/S0033291715002809
Disruptive mood dysregulation disorder at the age of 6 years and clinical and functional outcomes 3 years later
Abstract
Background: Little is known about the predictive validity of disruptive mood dysregulation disorder (DMDD). This longitudinal, community-based study examined associations of DMDD at the age of 6 years with psychiatric disorders, functional impairment, peer functioning and service use at the age of 9 years.
Method: A total of 473 children were assessed at the ages of 6 and 9 years. Child psychopathology and functional impairment were assessed at the age of 6 years with the Preschool Age Psychiatric Assessment with parents and at the age of 9 years with the Kiddie-Schedule of Affective Disorders and Schizophrenia (K-SADS) with parents and children. At the age of 9 years, mothers, fathers and youth completed the Child Depression Inventory (CDI) and the Screen for Child Anxiety Related Disorders, and teachers and K-SADS interviewers completed measures of peer functioning. Significant demographic covariates were included in all models.
Results: DMDD at the age of 6 years predicted a current diagnosis of DMDD at the age of 9 years. DMDD at the age of 6 years also predicted current and lifetime depressive disorder and attention-deficit/hyperactivity disorder (ADHD) at the age of 9 years, after controlling for all age 6 years psychiatric disorders. In addition, DMDD predicted depressive, ADHD and disruptive behavior disorder symptoms on the K-SADS, and maternal and paternal reports of depressive symptoms on the CDI, after controlling for the corresponding symptom scale at the age of 6 years. Last, DMDD at the age of 6 years predicted greater functional impairment, peer problems and educational support service use at the age of 9 years, after controlling for all psychiatric disorders at the age of 6 years.
Conclusions: Children with DMDD are at high risk for impaired functioning across childhood, and this risk is not accounted for by co-morbid conditions.
Keywords: Disruptive mood dysregulation disorder; irritability; longitudinal studies.
Conflict of interest statement
Dr. Carlson has received funding from Glaxo Smith Kline, Bristol Myers Squibb, Pfizer, and Merck. The other authors report no financial relationships with commercial interests.
References
-
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th. Washington, DC: American Psychiatric Press; 2013.
-
- Axelson D, Birmaher B, Zelazny J, Kaufman J, Gill MK. The Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (K-SADS-PL) 2009 Working Draft. Advanced Centre for Intervention and Services Research, Western Psychiatric Institute and Clinic; 2009. Retrieved from http://www.psychiatry.pitt.edu/research/toolsresearch/ksads-pl-2009worki....
-
- Axelson D, Findling RL, Fristad MA, Kowatch RA, Youngstrom EA, Horwitz SM, Arnold LE, Frazier TW, Ryan N, Demeter C, Gill MK, Hauser-Harrington JC, Depew J, Kennedy SM, Gron BA, Rowles BM, Birmaher B. Examining the proposed disruptive mood dysregulation disorder diagnosis in the longitudinal assessment of mania symptoms study. Journal of Clinical Psychology. 2012;73:1342–1350. - PMC - PubMed
-
- Birmaher B, Brent D, Chiappetta L, Bridge J, Monga S, Baugher M. Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): A replication study. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:1230–1236. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
